Radhamangalam Janakiraman Ramamurthi, MD
Anesthesiology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ramamurthi’s office at (650) 498-7200 to ask if they take your plan before you enroll.
California Medical Board record
Licence A96327 · Current
Licensed to practise in California · since 2006 · expires 2028-07-31 · University of Madras, Thanjavur Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$267 in 2023
| 2023 | 1 | 2 | None | $267 |
| 2020 | 1 | 1 | None | $10 |
| 2019 | 2 | 15 | $100 | $1,681 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Eagle Pharmaceuticals | Byfavo | $267 | 2 payments
|
See all 2 published payments
| Eagle Pharmaceuticals | Meals · 2023-10-25 | Byfavo | $173 |
| Eagle Pharmaceuticals | Meals · 2023-04-21 | None | $94 |
See earlier years (2020, 2019)
2020: $10
| Ambu | None | $10 | 1 payment
|
2019: $1,681
| Pacira Pharmaceuticals | Exparel | $1,581 | 14 payments
|
| Comsort | Bridion | $100 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth To 2 Years · 2023 | Their institution | $189,557 |
| EAGLE PHARMACEUTICALS, INC. · Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures · 2023 | Their institution | $142,431 |
| Merck Sharp & Dohme LLC · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth To 2 Years · 2024 | Their institution | $7,519 |
| Merck Sharp & Dohme LLC · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth To 2 Years · 2025 | Their institution | $2,695 |
Professional record
- NPI
- 1811042047
- Licence
- CA A96327California A96327: Current · expires 2028-07-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207LP3000X (207LP3000X); Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2007-01-25
- NPI last updated
- 2024-04-11
- NPI record certified
- 2024-04-11
This is when the NPI record was last certified, not a medical board exam.